Cargando…
Phase-2 Trial of an Intensified Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant for Poor-Risk Leukemia
Patients with poor-risk leukemia have a high relapse rate despite allogeneic transplant. We report on the phase II trial of an intensified allogeneic transplant regimen whose aim was tolerable toxicity and durable remission. Study patients (n=30) had unfavorable first remission cytogenetics, progres...
Autores principales: | Stein, Anthony S., O’Donnell, Margaret R., Synold, Timothy W., Dagis, Andrew C., Tsirunyan, Anjela, Nademanee, Auayporn P., Parker, Pablo M., Pullarkat, Vinod A., Snyder, David S., Spielberger, Ricardo T., Wong, Jeffrey Y.C., Alvarnas, Joseph C., Thomas, Sandra H., Forman, Stephen J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203202/ https://www.ncbi.nlm.nih.gov/pubmed/21151180 http://dx.doi.org/10.1038/bmt.2010.295 |
Ejemplares similares
-
Protective Effect of HLA-DPB1 Mismatch Remains Valid in Reduced-Intensity Conditioning Unrelated Donor Hematopoietic Cell Transplantation
por: Malki, Monzr M. Al, et al.
Publicado: (2019) -
Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021) -
Treatment of allosensitized patients receiving allogeneic transplantation
por: Ciurea, Stefan O., et al.
Publicado: (2021) -
The Confirmation of Safety for the Intensified Conditioning Regimens: A Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Remission Hematological Malignant Diseases
por: Yoshida, Shuro, et al.
Publicado: (2018) -
Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation
por: Zhu, Jinye, et al.
Publicado: (2023)